Zydus and Torrent Pharma Partner on Co-Marketing Agreement for Semaglutide Injection

Licensing and Supply Agreement for Semaglutide Injection in India

Zydus Lifesciences and Torrent Pharmaceuticals have entered into a licensing and supply agreement to co-market Semaglutide Injection, a diabetes treatment medication, in the Indian market.

Key Terms of the Agreement:

• Zydus will manufacture and supply the product, while Torrent Pharma has received semi-exclusive rights to co-market the product in India under its own brand name Sembolic.
• Torrent Pharma will leverage its strong presence in chronic therapies and extensive field force across the country to promote the product.
• Torrent Pharma will pay an upfront licensing fee to Zydus as part of the agreement.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

Product Details:

• Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a reusable pen device.
• Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus and chronic weight management in adults.

Financial Implications:

• The upfront licensing fee paid by Torrent Pharma to Zydus will contribute to the latter's revenue streams.
• The agreement is expected to enhance the market presence of Zydus and Torrent Pharma in the Indian pharmaceutical market.

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year